Abstract:Our appreciation of mitochondrial disease, in the context of both genetic and phenotypic heterogeneity, has blossomed over recent years with successive epidemiological studies, accrued clinical expertise and scientific advances. Epidemiological studies have encountered numerous obstacles, most importantly the initial recognition and diagnosis of a rare and variable multisystem disorder, but also complex referral pathways, specific and evolving diagnostic techniques, impaired penetrance and heteroplasmic mtDNA mutations, and the potential for ascertainment bias in disease cohorts. These inherent difficulties have contributed to both historical over- and under-representation of specific mtDNA or nuclear DNA-related mitochondrial disease. The last three decades have seen over 250 pathogenic mtDNA mutations identified, and the evolution of whole-genome sequencing is now identifying increasing numbers of pathogenic nuclear disease genes. Only recently has it been possible to estimate the prevalence of disease due to mutations of both the nuclear and mitochondrial genomes. To date, the most detailed prevalence figures available report the number of adults suffering from all forms of mitochondrial disease to be in the region of 12.5 per 100,000 of the population. One in 4300 people (23 per 100,000) carry pathogenic mutations of either nuclear or mtDNA and either have disease or are at risk of disease in the future. The most prevalent single mutation to cause mitochondrial disease is now recognised to be due to the m.3243A>G mutation in the MT-TL1 gene with a disease estimation of 3.5 per 100,000. Childhood-onset mitochondrial disease has been predicted to range from 0.5 to 1.5 cases per 100,000, approximately one-tenth of that seen in adults. Although no true population-based prevalence studies have yet been performed using laborious whole-genome sequencing, most existing studies focus on screening for individual mutations within cohorts felt to represent either the general population or the particular disease-defined cohorts. A small number of specific mtDNA mutations have been identified as causing a proportion of disease in diabetes, deafness and optic neuropathy cohorts. Although often considered a hallmark of mitochondrial disease, the prevalence of diabetes in most forms of mitochondrial disease is no higher than 10–12% as compared with a prevalence in the general population of 4.5%. The recognised association can be mainly attributed to the prevalent m.3243A>G mutation which frequently presents with maternally inherited deafness and diabetes. Deafness is common among many mtDNA mutations, usually as part of a broader phenotype, but can be the sole manifestation in the m.1555A>G mutation, particularly following exposure to aminoglycoside antibiotics. Leber’s hereditary optic neuropathy (LHON) occurs as a result of three common mutations in 90% of affected patients, with the point prevalence of disease standing at 3.7 per 100,000.The provision and development of highly specialised services, prospective cohort studies and use of objective clinical rating scales have contributed heavily to our understanding of the mitochondrial disorders today, and are likely to be instrumental in achieving more accurate epidemiological studies in mitochondrial disease in the future.

A systematic review on the biochemical threshold of mitochondrial genetic variants

Bioinformatics Tools and Databases to Assess the Pathogenicity of Mitochondrial DNA Variants in the Field of Next Generation Sequencing

Epidemiology of Mitochondrial Disease

Evaluation of the YSI 2300 glucose analyzer: algorithm-corrected results are accurate and specific.

Impact of the m.13513G>A Variant on the Functions of the OXPHOS System and Cell Retrograde Signaling

Acetaminophen hepatotoxicity and malnutrition.

Pathogenesis of mtDNA point mutation m.10191T>C affecting complex I function is a multifactorial process leading to metabolic remodeling of mitochondria

Association analysis of mitochondrial DNA heteroplasmic variants: methods and application

A cryptic pathogenic NDUFV1 variant identified by RNA-seq in a patient with normal complex I activity in muscle and transient magnetic resonance imaging changes

Biomarkers of mitochondrial disorders

Untargeted proteomics enables ultra-rapid variant prioritization in mitochondrial and other rare diseases

Enhanced mitochondrial genome analysis: bioinformatic and long-read sequencing advances and their diagnostic implications

Quantitative evaluation of the mitochondrial DNA depletion syndrome

Bioenergetic consequences of accumulating the common 4977-bp mitochondrial DNA deletion

Abstract 10452: Exploring the Role of Mitochondrial Genetic Variants in Coronary Artery Disease

Origins of tissue and cell-type specificity in mitochondrial DNA (mtDNA) disease

Mitochondrial Russian doll genes may explain some discrepancies in links between mtDNA mutations and mitochondrial diseases

Decoding the mitochondria without a code: mechanistic insights into mitochondrial DNA depletion syndromes

Impact of the mitochondrial genetic background in complex III deficiency

Analysis of the mitochondrial complex I-V enzyme activities of peripheral leukocytes in oxidative phosphorylation disorders.

Mitochondrial medicine therapies: rationale, evidence, and dosing guidelines